Clinical study

The study suggests that serum zinc by itself may not be a reliable indicator of endoscopic inflammation in UC; nutritional status and inflammation (for example albumin and CRP) can confound zinc levels.

Based on the title and source metadata, this appears to be a clinical study related to Crohn's disease, Inflammatory bowel disease, and Research and clinical trials. The original article is from idp.nature.com.

Based on the title and source metadata, this appears to be a clinical study related to Ulcerative colitis, Inflammatory bowel disease, and Tests and monitoring. The original article is from BMC Gastroenterology.

Long-term real-world data on filgotinib help patients and clinicians understand how durable benefits and risks are over 2 years, including likelihood of staying on therapy and changes in inflammation markers.

Based on the title and source metadata, this appears to be a clinical study related to Inflammatory bowel disease, Depression, and Research and clinical trials. The original article is from Cellular and Molecular...

This study provides real-world data suggesting the oral α4-integrin antagonist carotegrast methyl can improve patient-reported stool frequency and rectal bleeding in many people with ulcerative colitis who did not...

The study suggests that correcting low vitamin D in people with IBD may shift immune responses toward tolerance of gut microbes and associate with lower inflammation—information that could affect monitoring and...

Systemic glucocorticoids used for UC can cause bone loss; identifying early, noninvasive markers could let clinicians detect steroid-induced osteoporosis sooner and intervene to reduce fracture risk.

Microbiome composition differed between relapse and remission in ulcerative colitis in this study; specific bacterial and fungal taxa were statistically associated with clinical and endoscopic activity and are proposed...

The intestinal mucosal barrier is central to ulcerative colitis. If probiotics can strengthen that barrier, they might reduce inflammation or help maintain remission. This review summarizes mechanistic and early clinical...

A PopPK model for subcutaneous infliximab could enable more personalized dosing when starting or switching patients to home-administered infliximab, potentially improving drug exposure and management for people with IBD.

This study suggests that even when people with IBD are in clinical and biological remission on long-term biologic therapy, their gut microbiome composition and inferred functions can still differ from laboratory...

AI-assisted detection tools and disease-specific optical classifications could improve lesion detection and real-time characterization during UC surveillance, potentially affecting surveillance accuracy and...

If you or your clinician are choosing between advanced therapies for ulcerative colitis, this study suggests past vedolizumab use may be linked to lower likelihood of responding to ustekinumab.

If validated, prealbumin — a routine blood protein test reflecting nutrition and inflammation — could help predict who with Crohn’s disease is more likely to need abdominal surgery or to have endoscopic recurrence after...

Patients with IBD who may need dupilumab for another immune condition could benefit from evidence about whether combining dupilumab with IBD biologics or advanced therapies changes infection or healthcare-utilization...

Finding genetic variants that correlate with country-level IBD burden could help researchers study why IBD rates differ geographically and point to biological pathways relevant to disease risk and outcomes.

This project seeks new biology-based treatments for IBD by finding bacterial enzymes that block PAR signaling, a pathway linked to inflammation, barrier loss, and pain — symptoms many people with Crohn’s disease or...

Researchers are studying how gut bacteria evade therapeutic phages, which could affect development of phage-based treatments for drug-resistant infections and potentially influence understanding of bacteria linked to IBD...

Malnutrition and impaired growth are common at diagnosis in paediatric IBD—especially Crohn’s disease—and identifying these issues early can guide nutrition and treatment planning. Most underweight children in this study...

Fecal calprotectin is commonly used to monitor IBD activity. If bowel prep raises calprotectin modestly, that could affect how post-procedure results are interpreted and avoid unnecessary treatment changes.

Antibiotics can substantially change gut microbes; for people with IBD those changes may affect inflammation and gut barrier function. The review summarizes microbiome-targeted strategies that patients and clinicians may...

Consistent, accurate endoscopic scoring matters for treatment decisions and trial outcomes in pediatric IBD. If focused training meaningfully improves scoring—especially for SES‑CD—it could reduce variability in clinical...

This study suggests a specific four-strain probiotic cocktail may better protect against experimental colitis than the three-strain mix, potentially via microbiota-driven increases in spermidine — a microbial metabolite...

Distinguishing colorectal cancer from IBD-related inflammatory thickening can be challenging but crucial for treatment decisions. If validated, DECT parameters could offer a noninvasive tool to improve diagnostic...

This study provides real-world evidence about using upadacitinib as a maintenance therapy in children with refractory Crohn’s disease — a group with limited treatment options.

This study compares bloodstream infection risk across commonly used biologics for IBD, which could affect decisions about choosing or monitoring biologic therapy. It also highlights that steroid co-use may increase...

If true, prenatal and early-life exposures could influence long-term IBD risk by shaping immune development and the gut microbiome, which may help explain why some people develop IBD and others don’t.

The study suggests active smoking reduces the effectiveness of anti-TNF biologics in people with IBD, which could affect treatment response and the need to switch or escalate therapies. This supports including smoking...

High first-use usability suggests MyTARGET could be acceptable to many adults with IBD and that targeted refinements (error handling, demonstrating time savings) might improve uptake and recommendation.

A bibliometric map of perianal fistula research helps patients and clinicians see how much work exists, which centers and authors lead the field, and which topics cluster together—useful when looking for expertise or...

Noninvasive fecal biomarkers are widely used to track IBD activity. Knowing whether different FC assays give comparable results and whether combining tests adds value affects how patients and clinicians interpret...

Malnutrition is common but under-recognized in ulcerative colitis; a simple, more sensitive screening tool could help clinicians find patients who need nutritional assessment and support earlier.

The study suggests ulcerative colitis shows greater mucosal immune variability across sex, age and severity than Crohn’s disease, which could affect how patients are grouped for research or future personalized...

If you have UC, bowel urgency may indicate active inflammation more reliably than some other symptoms. Recognizing urgency could help prompt timely objective testing and treatment decisions.

Based on the title and source metadata, this appears to be a clinical study related to Ulcerative colitis, Inflammatory bowel disease, and Guselkumab. The original article is from Clinical gastroenterology and hepatology...

This study compares two commonly used biologics as first-line therapy for moderate-to-severe ulcerative colitis and reports better short- and long-term effectiveness for vedolizumab with similar safety. The results could...

Researchers used clustering on mixed clinical and treatment data to identify distinct Crohn's disease course trajectories and a small high-burden subgroup. If validated, such trajectories might help inform prognosis and...

A simple blood lymphocyte percentage could be a convenient, non-invasive marker to help distinguish endoscopic remission from active disease in both Crohn’s and ulcerative colitis; chemokines CXCL10 and CCL25 may also...

The report explores NOD2/CARD15 variants in a Djiboutian IBD cohort and suggests higher variant frequencies in Crohn’s disease, which could point to population-specific genetic susceptibility. It also raises khat use as...

The paper links specific gut bacteria, inflammatory cytokines, and two microRNAs with UC activity, which could point toward new diagnostic biomarkers or targets for research into disease mechanisms.

Persistent diarrhea is a common, quality-of-life–limiting problem in ulcerative colitis; this review synthesizes how epithelial transport, barrier damage, immune signaling, mitochondria, and microbiota interact and...

People with IBD or their clinicians may worry that systemic antifungal treatment could trigger flares.

This study compares two JAK inhibitors (upadacitinib and tofacitinib) used as rescue therapy for acute severe ulcerative colitis and reports lower 1‑year colectomy rates with upadacitinib. That could influence choices...

Automated, validated grading of UC on colonoscopy images could reduce variability between endoscopists and help standardize severity assessment that influences treatment planning.

Early prediction of who will not respond to infliximab could help clinicians avoid prolonged ineffective treatment, enabling earlier reassessment and changes in therapy as part of treat-to-target care.

Patients and clinicians often need evidence about whether switching from ustekinumab to an anti‑TNF (infliximab or adalimumab) still gives meaningful clinical responses. This study suggests many patients can respond, but...

Obese patients with FibroScan-detected steatosis in this cohort had a high frequency of colitis and some cases of IBD, dysplasia, and cancer, which could affect screening and symptom evaluation decisions.